Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.94% is in line with its 5-year average of 1.00%, near the high end of its 5-year range (0.00%–1.19%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.78% above its 12-month average of 0.90%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.94%.
DEBT TO ASSETS RATIO
0.94%
DEBT TO ASSETS RATIO AVG TTM
0.90%
DEBT TO ASSETS RATIO AVG 3Y
0.96%
DEBT TO ASSETS RATIO AVG 5Y
1.00%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+4.78%
CURRENT VS 3Y AVG
-2.15%
CURRENT VS 5Y AVG
-5.57%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+844.08%
vs the sector median at left
Design Therapeutics, Inc.
Market Cap
$748.66M
Debt to Assets Ratio
0.94%
TTM Avg
0.90%
3Y Avg
0.96%
5Y Avg
1.00%
Market Cap
$753.89M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$745.00M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$742.59M
Debt to Assets Ratio
0.24%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$768.50M
Debt to Assets Ratio
0.24%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$770.19M
Debt to Assets Ratio
0.24%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$715.08M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$711.94M
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $748.66M | 0.94% | 0.90% | 0.96% | 1.00% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $753.89M | 0.03% | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $745.00M | 0.06% | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $742.59M | 0.24% | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $768.50M | 0.24% | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $769.83M | 0.24% | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $770.19M | 0.24% | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $715.08M | 0.00% | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $711.94M | 0.08% | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.53M | 0.40% | N/A | N/A | N/A |
Debt/Assets
0.9%
Debt/Equity
0.01
Current Ratio
18.86
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.94% |
| 2026-03-31 | 1.19% |
| 2025-12-31 | 0.68% |
| 2025-09-30 | 0.82% |
| 2025-06-30 | 0.87% |
| 2025-03-31 | 0.90% |
| 2024-12-31 | 0.93% |
| 2024-09-30 | 0.96% |
| 2024-06-30 | 1.00% |
| 2024-03-31 | 1.03% |
| 2023-12-31 | 1.05% |
| 2023-09-30 | 1.07% |
| 2023-06-30 | 1.08% |
| 2023-03-31 | 1.09% |
| 2022-12-31 | 1.08% |
| 2022-09-30 | 1.08% |
| 2022-06-30 | 1.08% |
| 2022-03-31 | 0.93% |
| 2021-12-31 | 0.93% |
| 2021-09-30 | 0.94% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
